AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02285621 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimized brace versus conventional Boston brace
Description: Surface topography using Inspeck cameras allows production of a 3D reconstruction of the patient's trunk, this reconstruction will help to produce the optimized brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between time points. All radiographs will be taken with an EOS imaging system to allow 3D reconstructions. The SRS-22r will be collected at all clinical visits. Study questions will be aligned as much as possible with other prospective scoliosis protocols so as to minimize patient and surgeon response burden. The study protocol requires no additional visits or radiographs beyond standard of care. Ibuttons are installed in each brace and used to measure the compliance of the patient.
Study NCT02656485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B244
Description: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
Study NCT02656485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B244
Description: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
Study NCT02656485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
Study NCT02081781 — intervention group
Intervention type: PROCEDURE
Intervention: Probing
Description: A punctal dilator was used for dilating the punctum. The nasolacrimal system was irrigated through either the lower or upper punctum with a hollow 23-gauge irrigating cannula attached to a syringe. A #0 (or #00) Bowman probe was passed through either the lower or upper canaliculus into the lacrimal sac and then directed downward through the nasolacrimal duct into nasal cavity. A Hard resistance could be felt as the probe touched the end of the nasolacrimal duct. A Pop tactile sensation might be noted while the probe passing through an obstruction at the valve of Hasner.
Study NCT02210767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnut Diet
Description: 2 oz. walnuts/day (2-3% of total calories from ALA)
Study NCT02210767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walnut Control Diet
Description: 2-3% ALA but no walnuts provided
Study NCT02210767 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low ALA Diet
Description: ALA replaced by oleic acid
Study NCT02789306 — intervention group
Intervention type: PROCEDURE
Intervention: Epidemiological study on the incidence of peri-implantitis
Description: Clinical and radiographic examination in the routine based protocol
Study NCT01540175 — intervention group
Intervention type: OTHER
Intervention: Blood samples obtained
Description: Research participants agree to have blood samples obtained at the time of diagnosis before any chemotherapy, if available, and prior to high dose chemotherapy regimen with autologous HSCT as well as on days 14, 21, 28, week 8 and months 3, 6, 12 and 18 after autologous HSCT. Research participants with high risk neuroblastoma may also agree to have blood samples taken before and twice in the recovery period (days 0, 7 and 15-18) of Induction chemotherapy courses one and four.
Study NCT00096395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT03913507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macroduct® Advanced Model 3710 SYS, Wescor
Description: for each subject, both methods will be tested in order to compare the efficacy of the new sweat collection method (Macroduct® Advanced Model 3710 SYS, Wescor) to the method currently used in clinical routine.
Study NCT00096395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00096395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03082781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NCDsport
Description: Negative Calorie Diet supplemented with exercise
Study NCT03082781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LCDsport
Description: Low-Calorie diet with exercise
Study NCT02142244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near infra red sentinel node biopsy
Description: Explicated in the protocol arm
Study NCT02142244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Explicated in the protocol arm
Study NCT02142244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative Near-Infrared Imaging System
Description: Explicated in the protocol arm
Study NCT01134081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CelTx™
Description: CelTx™ is a living bilayered cell therapy product. CelTx™ is constructed of Type I bovine collagen (extracted from bovine tendons and subsequently purified) and viable allogeneic human fibroblasts and keratinocytes isolated from human neonatal foreskin. This is applied once in the oral cavity.
Study NCT03630315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TKI
Description: OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
Study NCT03630315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF
Description: Standard of care therapy used to block vascular endothelial growth factor
Study NCT02061488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: open-loop night
Description: During the open-loop night the patient is using his insulin pump as usual
Study NCT01134081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft
Description: Harvested tissue from palate
Study NCT02909140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical phenylephrine 2.5%
Study NCT02909140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical cyclopentolate 1%
Study NCT02909140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracameral Lidocaine 1%
Study NCT02909140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracameral 0.2- 0.3ml of epinephrine 1:10,000
Study NCT00417209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotaxel (XRP9881)
Description: administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
Study NCT00417209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: administered as IV infusion from Day 1 to Day 4
Study NCT00417209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: administered orally from Day 1 to Day 14 q3w
Study NCT01989728 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychiatric examination and feedback
Study NCT01989728 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychiatric examination and feedback
Study NCT02217865 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interviews - Colorectal Cancer Participants
Description: Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
Study NCT02217865 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire completion asking general health and demographic questions.
Study NCT02061488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: closed-loop night
Description: During the closed-loop night glucose values measured by the sensor are collected every 15 minutes. The data are entered into the SP-MPC controler that calculate the insulin dose to be delivered. A diabetologist validates the insulin dose before the infusion (manually bolus infusion)
Study NCT01954446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M
Description: Conventional measuring of BP
Study NCT01954446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ContiPressTM
Description: New way of measuring BP - ContiPressTM~Investigational device
Study NCT01954446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobil-O-Graph
Description: 2 different devices for oscillometric measurement of BP
Study NCT02217865 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: Focus groups conducted with participants and caregivers. Up to 4 focus groups conducted with up to 30 participants each. Focus groups expected to take 30 to 60 minutes.
Study NCT02217865 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interviews - Caregivers of Colorectal Cancer Participants
Description: Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
Study NCT00842842 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tack fixation of mesh
Description: tack fixation of mesh
Study NCT00842842 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glue fixation of mesh
Description: glue fixation of mesh
Study NCT00678366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: addition of 4% oxygen
Description: addition of 4% oxygen to the carbon dioxide pneumoperitoneum
Study NCT00678366 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carbon dioxde
Description: classic pneumoperitoneum with 100 % carbon dioxide
Study NCT03744416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling based on Epstein's active decision making
Description: Birth information leaflet. Based on the best evidence practice. Midwives' training on share decision making based on Epstein model. Pregnant intervention. The pregnant women will receive from the midwives the birth plan (BP) in the prenatal check at the health center, between the 24-28 weeks, to be completed at home. Later, on the visit between 29-33 weeks, the midwives will provide the birth information leaflet and carry out the counseling intervention based on shared decision making to the pregnant women. As well, midwives will deliver a second BP that pregnant woman will fill at home. On the prenatal check between 34 to 40 weeks, the midwife will save a copy of the latest BP. The midwife will instruct the woman to deliver the BP when she arrives to the hospital for birth.
Study NCT03765632 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)
Description: Autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
Study NCT03765632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan is used for non-myeloablative conditioning
Study NCT03765632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-Ada
Description: Peg-Ada Enzyme Replacement Therapy (ERT) is discontinued at Day +30 (-3/+15 days) after successful engraftment
Study NCT02068482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
Study NCT00418470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regular dilution of antibiotic in NS
Description: IV administration of ceftazidime tid diluted in regular NS volume
Study NCT00418470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: higher dilution of antibiotic in NS
Description: IV administration of ceftazidime tid diluted in larger NS volume
Study NCT00633282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life style intervention
Description: calorie limited diet: to subtract 500 kcal from daily mean calorie intake when entering the treatment~activity: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate; or higher-intensity aerobic exercise for more than 90min per week with heart rate around 70% of the maximal heart rate
Study NCT00633282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: pioglitazone tablet,15mg qd ,30 minutes before breakfast,for 16 weeks
Study NCT00633282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: berberine
Description: berberine tablet 0.5g tid,30 minutes before each meal,for 16 weeks
Study NCT03196999 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Attention Bias Training
Description: This self-help program will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be personalized for each user.
Study NCT03196999 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Attention Training Condition
Description: This self-help program is a placebo control program that will be used on an iOS compatible phone. The placebo will contain only neutral words.
Study NCT03196999 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Personalized Attention Bias Training
Description: This self-help program administered on an app will aim to reduce neurobiological threat sensitivity with the ultimate goal of a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same for each user.
Study NCT02433665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol
Description: Iopamidol is the contrast material being used for this study. 100 subjects will receive a fixed dose and rate (150 mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of 3 mL/sec for a total dose of 45 grams of iodine) and 400 subjects will be administered a customized dose and rate (X mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of X mL/sec for a total dose of X grams of iodine).
Study NCT02433665 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mydose
Description: 400 subjects will receive a customized dose of contrast material (iopamidol) based on the experimental algorithm Mydose using a combination of subject parameters.
Study NCT02030184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhenium Re 188-P2045
Description: Topotecan at 1.0 mg/m2 or 1.5 mg/m2 for 3 days, followed by single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
Study NCT01259869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866
Description: 1 cycle = 8 weeks on study PX-866 - 8mg PO Daily
Study NCT03304600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active stimulation
Description: Patients will receive a tDCS stimulation during 30 mn with an intensity of 2 milliampere (mA).
Study NCT03304600 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Patients will receive a Sham stimulation during 30 mn
Study NCT03238677 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech Motor Chaining without Biofeedback
Description: These procedures target sound sequences (consonant-vowel, consonant-consonant, or vowel-consonant). Sessions begin with Pre-practice to elicit the target sounds, with verbal cueing and shaping strategies. The Practice component then includes chaining that is response-contingent. Participants practice in blocks of 6 consecutive trials beginning at the syllable level. If 5/6 are correct, the participant advances to monosyllabic word practice, then multisyllabic word practice, phrase practice, and sentence practice (with the target syllable embedded within each level of complexity). If fewer than 5/6 trials are correct, a different syllable with the target sound pattern is practiced next. Verbal feedback is faded from 5 of 6 trials at the syllable level to only 3 of 6 trials at the sentence level. For more description, see http://speechproductionlab.syr.edu/Resources%20for%20Researchers.html
Study NCT03238677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Motor Chaining without Biofeedback
Description: These procedures target sound sequences (consonant-vowel, consonant-consonant, or vowel-consonant). Sessions begin with Pre-practice to elicit the target sounds, with verbal cueing and shaping strategies. The Practice component then includes chaining that is response-contingent. Participants practice in blocks of 6 consecutive trials beginning at the syllable level. If 5/6 are correct, the participant advances to monosyllabic word practice, then multisyllabic word practice, phrase practice, and sentence practice (with the target syllable embedded within each level of complexity). If fewer than 5/6 trials are correct, a different syllable with the target sound pattern is practiced next. Verbal feedback is faded from 5 of 6 trials at the syllable level to only 3 of 6 trials at the sentence level. For more description, see http://speechproductionlab.syr.edu/Resources%20for%20Researchers.html
Study NCT03238677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Real-time images of the tongue are made available using ultrasound placed beneath the chin. Participants practice speech movements and can be cued to modify their tongue shape or position to achieve clearer speech. Practice structure is similar to the Speech Motor Chaining procedures, but with the addition of a visual reference.
Study NCT03238677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distributed Practice
Description: 2 sessions per week for 10 weeks
Study NCT03238677 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Distributed Practice
Description: 2 sessions per week for 10 weeks
Study NCT03238677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massed --> Distributed Practice
Description: Week 1: 10 hours of treatment Week 2: 3 hours of treatment Week 3: 3 hours of treatment Week 4: 2 hours of treatment Week 5: 2 hours of treatment
Study NCT04318665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT Perfusion
Description: Severe Traumatic Brain Injury patients will be undergoing CT perfusion test
Study NCT04418726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensified Monitoring
Description: Apart from clinical assessment, use non-invasive devices to check for the haemodynamic consequences of stenosis by measuring Qa, using either indicator dilution techniques or duplex ultrasound every month.
Study NCT01298570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib (BAY 73-4506)
Description: Regorafenib, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
Study NCT01298570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
Study NCT01298570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
Study NCT01298570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFIRI
Description: FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
Study NCT03500484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide will be supplied in the following package sizes containing disposable, pre-filled, multidose pens. Each individual pen delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg (6 mg/mL, 3 mL). Liraglutide will be self-administered daily for 12 weeks under the following regimen: 0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, 3.0mg until week 12.
Study NCT01243554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise training at the hospital
Study NCT02498548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trained SCI Knee or Trained SCI Hip
Description: Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of knee control or hip control, members of this group will be trained at slow to moderate gait speeds.
Study NCT00925314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CB-10-01 (Transgenic Lymphocyte Immunization)
Description: 1 Primary Infusion and 2 Booster Infusions
Study NCT03172780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium gel 1%
Description: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
Study NCT03172780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%
Description: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
Study NCT03172780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Vehicle Gel 4 gm, 4 times a day for 4 weeks
Study NCT01969357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets(n=4),once daily for 84 days
Study NCT01969357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg SP2086
Description: Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days